Researchers at West Virginia University assessed the impact of THC administration in an animal model of NSAID-induced gastric inflammation. Investigators reported that low doses of THC provided gastroprotective effects, significantly attenuating gastric hemorrhages and lesions. They concluded, “[C]annabinoids may have the added benefit of reducing the effective analgesic dose of NSAIDs, as well as reducing the incidence of NSAID-induced gastric ulcers.”
Inhaling cannabis reduces symptoms of Crohn’s disease compared to placebo in patients non-responsive to traditional therapies, according to clinical trial data published online ahead of print in the journal Clinical Gastroenterology and Hepatology. The study is the first placebo-controlled clinical trial to assess the consumption of cannabis for the treatment of Crohn’s.